Table 1.
n | Mean | Range | |
---|---|---|---|
Patients (n) | 50 | ||
Age (years) | 67 | 41 to 77 | |
PSA (ng/ml) | 37 | 2.7 to 168 | |
Gleason score | 8 | 6 to 10 | |
Estimated risk of locoregional lymph node metastases (%)a | 32 | 3.3 to 80.3 |
aAccording to the Cagiannos pre-treatment nomogram, where age, pre-treatment PSA, clinical tumour stage, primary and secondary Gleason grade, and the number of positive and negative biopsy cores influence the estimated risk.